In Situ Hybridization, Fluorescence
"In Situ Hybridization, Fluorescence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
| Descriptor ID |
D017404
|
| MeSH Number(s) |
E01.370.225.500.620.670.325.350 E01.370.225.750.600.670.325.350 E05.200.500.620.670.325.350 E05.200.750.600.670.325.350 E05.393.285.350 E05.393.661.475.350
|
| Concept/Terms |
In Situ Hybridization, Fluorescence- In Situ Hybridization, Fluorescence
- Hybridization in Situ, Fluorescent
- FISH Technique
- FISH Techniques
- Technique, FISH
- Techniques, FISH
- Fluorescent in Situ Hybridization
- FISH Technic
- FISH Technics
- Technic, FISH
- Technics, FISH
- Hybridization in Situ, Fluorescence
- In Situ Hybridization, Fluorescent
|
Below are MeSH descriptors whose meaning is more general than "In Situ Hybridization, Fluorescence".
Below are MeSH descriptors whose meaning is more specific than "In Situ Hybridization, Fluorescence".
This graph shows the total number of publications written about "In Situ Hybridization, Fluorescence" by people in this website by year, and whether "In Situ Hybridization, Fluorescence" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 6 | 7 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 4 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "In Situ Hybridization, Fluorescence" by people in Profiles.
-
Primary Thyroid Mucoepidermoid Carcinoma (MEC) Is Clinically, Prognostically, and Molecularly Different from Sclerosing MEC with Eosinophilia: A Multicenter and Integrated Study. Endocr Pathol. 2023 Mar; 34(1):100-111.
-
NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review. Curr Oncol. 2021 11 07; 28(6):4485-4503.
-
Lipoma or Liposarcoma? Robotic Resection of a Retroperitoneal Mass. J Obstet Gynaecol Can. 2022 10; 44(10):1095-1096.e1.
-
Secretory Carcinoma of the Skin: Report of 6 Cases, Including a Case With a Novel NFIX-PKN1 Translocation. Am J Surg Pathol. 2019 08; 43(8):1092-1098.
-
Advances in the diagnosis and surveillance of Barrett's esophagus (with videos). Gastrointest Endosc. 2019 09; 90(3):325-334.
-
Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples. BMC Cancer. 2019 Jan 28; 19(1):106.
-
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. PLoS One. 2018; 13(1):e0191244.
-
Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. World Neurosurg. 2017 Dec; 108:997.e9-997.e14.
-
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018 06; 59(6):1338-1347.
-
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol. 2017 05; 12(5):804-813.